Retatrutide vs Mazdutide

Retatrutide vs Mazdutide: Overview

Retatrutide and mazdutide represent two of the most advanced multi-receptor agonist peptides in clinical development for metabolic disease, each incorporating glucagon receptor agonism as a core component of their pharmacological mechanism. Retatrutide (LY3437943), developed by Eli Lilly, is a triple-hormone receptor agonist that engages GIP, GLP-1, and glucagon receptors simultaneously. Mazdutide (IBI362/LY3305677), developed by Innovent Biologics, is a dual GLP-1/glucagon receptor agonist. The comparison of mazdutide vs retatrutide is particularly compelling because both agents leverage glucagon receptor activation to enhance metabolic outcomes beyond what single GLP-1 receptor agonism achieves.

The question of whether the additional GIP receptor agonism present in retatrutide — making it a triple agonist versus mazdutide’s dual agonist approach — translates into meaningfully greater clinical efficacy is central to this comparison. Research suggests that the incremental metabolic benefit of GIP receptor activation on top of dual GLP-1/glucagon agonism may involve enhanced insulin sensitivity, improved adipose tissue function, and complementary appetite-suppressive effects. Understanding how retatrutide vs mazdutide compares across efficacy, safety, and pharmacokinetic parameters provides insight into the emerging hierarchy of multi-agonist metabolic therapies.

Both compounds are in active clinical development, with phase 2 and phase 3 data now available. Their shared incorporation of glucagon receptor agonism — targeting hepatic lipid metabolism, energy expenditure, and thermogenesis — positions them as particularly relevant for research into metabolic-associated steatotic liver disease and related conditions, beyond their weight loss and glycaemic effects.

Mechanism of Action

Retatrutide functions as a triple-hormone receptor agonist, simultaneously engaging the GIP receptor, GLP-1 receptor, and glucagon receptor. This “triagonist” design represents the most comprehensive multi-receptor approach currently in clinical development. GLP-1 receptor activation provides the established metabolic benefits of glucose-dependent insulin secretion, glucagon suppression at the pancreatic alpha cell level, delayed gastric emptying, and central appetite reduction. GIP receptor activation contributes to enhanced insulin secretion, potential improvements in adipose tissue metabolism, and complementary satiety signalling. Glucagon receptor activation promotes hepatic glycogenolysis and gluconeogenesis acutely, but more importantly in this context, increases hepatic lipid oxidation, stimulates energy expenditure, and may enhance thermogenesis through mechanisms involving brown and beige adipose tissue activation.

Mazdutide, as a dual GLP-1/glucagon receptor agonist, shares the GLP-1 and glucagon receptor agonist components with retatrutide but lacks the GIP receptor engagement. The GLP-1 component provides glucose-dependent insulin secretion and appetite suppression, while the glucagon component drives energy expenditure and hepatic lipid metabolism effects. The balance between GLP-1 and glucagon agonism in mazdutide is calibrated to ensure that the glucagon-mediated increase in hepatic glucose output is offset by GLP-1-mediated insulin secretion, resulting in net glucose-lowering effects.

The mechanistic difference between these compounds thus centres on whether the addition of GIP receptor agonism in retatrutide provides clinically meaningful incremental benefits over mazdutide’s dual GLP-1/glucagon approach. Preclinical data indicates that the triagonist mechanism may produce synergistic effects on energy expenditure and appetite regulation that exceed what is achieved with dual agonism alone, though clinical data is needed to confirm this hypothesis.

Clinical Evidence

Retatrutide’s clinical programme produced landmark phase 2 results published by Jastreboff et al. in the New England Journal of Medicine in 2023. This phase 2 trial enrolled 338 adults with obesity and demonstrated unprecedented body weight reductions of up to 24.2% at 48 weeks with the highest dose evaluated (12 mg). These results represented the largest weight reduction achieved with any pharmacological agent in clinical trials at the time of publication. A qualitative study of participants in this phase 2 trial further documented the perceived benefits of treatment. Retatrutide has since advanced into phase 3 clinical trials, with the TRIUMPH programme evaluating its efficacy and safety across multiple metabolic indications.

Mazdutide’s clinical development has progressed through multiple phases, with data primarily generated in Chinese clinical populations. A phase 2 randomised controlled trial by Ji et al. evaluated mazdutide 9 mg in adults with BMI ≥30 kg/m² without diabetes, demonstrating significant weight reduction. Phase 3 trials published in Nature in 2026 compared mazdutide against placebo and against dulaglutide in Chinese adults with type 2 diabetes, demonstrating superiority in both comparisons for glycaemic control and body weight reduction. A high-dose phase 1 study by Bhattachar et al. characterised the pharmacokinetics and pharmacodynamics of mazdutide at doses designed to maximise weight loss.

No direct head-to-head clinical trial comparing retatrutide vs mazdutide has been conducted. Network meta-analyses incorporating both agents are beginning to emerge, with a comprehensive meta-analysis by Abulehia et al. examining the comparative efficacy and safety of glucagon receptor agonists on metabolic outcomes providing initial indirect comparison data.

Efficacy Comparison

The weight loss efficacy data for retatrutide and mazdutide, while derived from different trials and populations, suggests a meaningful gradient between the two agents. Retatrutide at 12 mg weekly in its phase 2 trial achieved mean body weight reductions of approximately 24%, with some participants achieving weight reductions exceeding 30%. These results positioned retatrutide as potentially the most efficacious weight loss pharmacotherapy in clinical development.

Mazdutide’s weight loss data from its phase 2 and phase 3 programme has demonstrated body weight reductions in the range of 8–15% depending on dose and population. While clinically meaningful, these reductions are more modest than those observed with retatrutide, consistent with the hypothesis that triple-receptor agonism provides incremental weight loss benefits over dual agonism. A network meta-analysis by Xie et al. examining seven GLP-1 receptor agonists and polyagonists for weight loss confirmed the dose-dependent and mechanism-dependent hierarchy of weight loss efficacy among these agents.

Regarding glycaemic outcomes, both agents have demonstrated robust HbA1c reductions. Retatrutide achieved HbA1c reductions of up to 2.2 percentage points in its phase 2 trial, while mazdutide’s phase 3 data has shown comparable glycaemic improvements. The glucagon receptor agonist component shared by both agents may confer particular advantages in hepatic fat reduction, a metabolic outcome of increasing clinical relevance given the growing prevalence of metabolic-associated steatotic liver disease.

Safety and Tolerability

Both retatrutide and mazdutide share the gastrointestinal adverse event profile characteristic of GLP-1 receptor-active therapies. Nausea, diarrhoea, vomiting, and decreased appetite are the most commonly reported adverse events with both compounds, following the dose-dependent escalation pattern typical of the class.

In retatrutide’s phase 2 trial, gastrointestinal adverse events were reported in approximately 35–50% of participants depending on the dose level, though the majority were mild to moderate in severity. Discontinuation rates due to adverse events were relatively low, supporting overall tolerability. The triple-agonist mechanism did not introduce unexpected safety signals beyond those anticipated from the individual receptor components. A review of the paradigm shift represented by retatrutide in multi-hormonal pharmacotherapy noted the generally manageable safety profile observed across dose levels.

Mazdutide’s safety profile from its phase 3 programme has been broadly consistent with other incretin-based dual agonists. The glucagon receptor component shared by both agents raises theoretical considerations regarding hepatic glucose output and potential hyperglycaemic effects, but clinical data indicates that concurrent GLP-1 receptor activation effectively mitigates this risk. Both agents carry the class-related precautions regarding thyroid C-cell tumour risk (based on rodent findings), pancreatitis, and gallbladder-related events.

Pharmacokinetics

Retatrutide is administered via once-weekly subcutaneous injection, with a half-life of approximately 6 days achieved through albumin binding via a fatty acid modification. The molecule is designed to achieve balanced engagement of all three receptor targets (GIP, GLP-1, and glucagon) with a pharmacokinetic profile that supports stable plasma concentrations throughout the weekly dosing interval. Steady-state concentrations are reached after approximately four to five weeks of weekly dosing.

Mazdutide is similarly administered via once-weekly subcutaneous injection, with structural modifications to achieve extended duration of action. The pharmacokinetic profile has been characterised through its phase 1 and phase 2 programme, with dose-proportional pharmacokinetics observed across the evaluated dose range. The high-dose phase 1 study provided detailed pharmacokinetic parameters supporting the once-weekly dosing regimen.

Both agents share the subcutaneous route and weekly dosing frequency, making them pharmacokinetically comparable from a practical administration perspective. The primary pharmacokinetic differences relate to their distinct molecular architectures and the differing tissue distribution patterns that may arise from their different receptor-binding profiles. Retatrutide’s triple-receptor engagement may result in broader tissue-level pharmacodynamic effects compared with mazdutide’s dual-receptor approach.

Current Research Status

Retatrutide is currently in phase 3 clinical development through the TRIUMPH programme, which encompasses multiple trials across obesity, type 2 diabetes, and metabolic-associated steatotic liver disease. Phase 2 results have generated considerable interest based on the unprecedented weight loss efficacy observed, and the phase 3 programme is designed to provide the registrational data required for regulatory submissions. Retatrutide does not yet hold regulatory approval in any jurisdiction.

Mazdutide has received regulatory approval in China for type 2 diabetes and continues to advance through its global clinical development programme. The DREAMS programme represents the primary registrational pathway for markets outside China, with the DREAMS-3 trial comparing mazdutide against semaglutide providing important comparative efficacy data. Mazdutide is further along the regulatory pathway than retatrutide, with approval in at least one major market, though global expansion continues.

Summary

The comparison of retatrutide and mazdutide illustrates the evolving landscape of multi-receptor agonist metabolic therapies. Both agents incorporate glucagon receptor agonism to enhance energy expenditure and hepatic lipid metabolism, but retatrutide adds GIP receptor agonism as a third receptor target. Phase 2 data suggests that retatrutide’s triple-agonist approach produces greater absolute weight loss (approximately 24% at the highest dose) compared with mazdutide’s dual-agonist results (approximately 8–15%). Both agents demonstrate robust glycaemic improvements and share the class-typical gastrointestinal tolerability profile. Mazdutide is further advanced in regulatory terms, with approval in China, while retatrutide is in phase 3 development. Direct head-to-head comparison data are not available, and the differing study populations (predominantly Chinese for mazdutide, global for retatrutide) complicate cross-trial comparisons.

References

• Jastreboff AM et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. PMID: 37366315
• Ji L et al. (2026). Mazdutide 9 mg in Chinese adults with a body mass index ≥30 kg/m² but without diabetes: A phase 2 randomized controlled trial. Med. PMID: 41875890
• Zhu D et al. (2026). Mazdutide versus placebo in Chinese adults with type 2 diabetes. Nature. PMID: 41407859
• Guo L et al. (2026). Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes. Nature. PMID: 41407860
• Bhattachar SN et al. (2025). Mazdutide reduces body weight in adults with overweight or obesity: A high-dose Phase 1 trial. Diabetes, Obesity and Metabolism. PMID: 40832785
• Abulehia A et al. (2026). Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis. Endocrinology, Diabetes & Metabolism. PMID: 41787737
• Xie Z et al. (2024). Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss: an updated systematic review and network meta-analysis. Metabolism. PMID: 39305981
• Bailey CJ et al. (2025). Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities. Peptides. PMID: 40081498